| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 |
Zydus Life Science
868.85
+24.45
(2.90%)
Market Cap
87,426.64 Cr
EPS
38.14
PE Ratio
18.74
Dividend Yield
0.36 %
Industry
Healthcare52 Week High
1,324.30
52 Week Low
795.00
PB Ratio
3.89
Debt to Equity
0.05
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from27 analysts
Company News
View All News
Zydus Lifesciences Receives FDA Approval for Deflazacort Tablets2 days ago
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (FDA) for Jaythari (Deflazacort) tablets in various strengths: 6 mg, 18 mg, 30 mg, and 36 mg. This approval allows the company to market these tablets in the United States.
Zydus Lifesciences: FDA Approves Jaythari for Duchenne Muscular Dystrophy3 days ago
Zydus Lifesciences received USFDA approval for Jaythari (Deflazacort) Tablets in 6 mg, 18 mg, 30 mg, and 36 mg strengths to treat Duchenne muscular dystrophy in patients 5 years and older. Manufacturing will occur at Doppel Farmaceutici S.r.l. in Italy. Zydus now has 424 USFDA approvals. The company also incorporated a subsidiary in France, Zydus MedTech (France) SAS.
Zydus Lifesciences: Establishes French Subsidiary for Amplitude Surgical Acquisition3 days ago
Zydus Lifesciences has incorporated a wholly owned subsidiary, Zydus MedTech (France) SAS, on April 10, 2025, to acquire an 85.6% stake in Amplitude Surgical SA for €256.8 million. The company plans a subsequent tender offer for remaining shares and potential delisting.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.55 | #1 4,04,899.77 | 33.61 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 47.60 | |
5,589.30 | 1,48,378.35 | 69.15 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 47.92 | |
1,463.05 | 1,18,158.10 | 22.92 | 26,520.70 | 14.17 | 4,155 | 47.38 | 50.89 | |
3,129.00 | 1,05,899.58 | 56.83 | 10,785.70 | 11.59 | 1,656 | 13.54 | 45.29 | |
2,350.50 | 96,976.58 | 46.77 | 10,615.60 | 19.57 | 1,942 | -16.38 | 48.68 | |
1,109.50 | 92,582.82 | #1 17.01 | 28,905.40 | 12.36 | 5,578 | 1.69 | 40.66 | |
1,969.25 | 89,904.33 | 30.58 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 46.62 | |
868.85 | #8 87,426.64 | #3 18.74 | #6 19,831.50 | #5 13.82 | #4 3,831 | #4 29.92 | 44.56 | |
29,641.10 | 62,985.27 | 46.40 | 6,097.20 | 10.80 | 1,201 | 16.01 | 48.36 | |
1,082.45 | 62,868.87 | 17.41 | 29,559.20 | 17.55 | 3,169 | -10.04 | 41.61 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
13.82 %
Net Income Growth
91.39 %
Cash Flow Change
20.05 %
ROE
70.50 %
ROCE
52.01 %
EBITDA Margin (Avg.)
23.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,228 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,810 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
3 days ago
3 days agoIncorporation Of A Wholly Owned Subsidiary In France3 days ago
3 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20185 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 16, 2025
Mar 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 14, 2025
Mar 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 08, 2025
Mar 08, 2025Revised ESG ScoreMar 05, 2025
Mar 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 05, 2025
Mar 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 05, 2025
Mar 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2025
Mar 04, 2025Demand Notice Received By Zydus Healthcare Limited A Wholly Owned Subsidiary Company From GST DepartmentMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Feb 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Feb 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 22, 2025
Feb 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Feb 06, 2025Intimation Of ESG RatingFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2025
Feb 05, 2025Integrated Filing (Financial)Feb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2025
Feb 05, 2025Board Meeting Outcome for Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2024Feb 05, 2025
Feb 05, 2025Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2024Feb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
Jan 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 26, 2025
Jan 26, 2025Demand Notice By GST DepartmentJan 25, 2025
Jan 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 22, 2025
Jan 22, 2025Demand Notice By GST DepartmentJan 21, 2025
Jan 21, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results Of The Company For The Quarter / Nine Months Ended On December 31 2024Jan 21, 2025
Jan 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 18, 2025
Jan 18, 2025Technical Indicators
RSI(14)
Neutral 44.56
ATR(14)
Less Volatile 32.72
STOCH(9,6)
Neutral 36.97
STOCH RSI(14)
Neutral 36.33
MACD(12,26)
Bearish -3.22
ADX(14)
Weak Trend 19.08
UO(9)
Bearish 50.97
ROC(12)
Downtrend And Accelerating -5.94
WillR(14)
Neutral -52.25
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(24 Years,
19 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
